Human Transporters

MRP2

Interested in FDA or EMA Compliant Transporter Studies?

MRP2 (multidrug resistance-associated protein 2)

Aliases: ABC30, CMOAT, DJS, cMRP
Gene name: ATP binding cassette subfamily C member 2 (ABCC2)

Summary

ABCC2, typically referred to as MRP2, is a unidirectional efflux transporter that primarily transports organic anions, including drug conjugates and conjugated bilirubin. Although expressed in numerous tissues in humans, particularly in the liver, kidney, gastrointestinal tract (GIT) and placenta, MRP2 has a more restricted tissue distribution than MDR1 or BCRP. MRP2 is most highly expressed in the liver, where it facilitates the elimination of bilirubin glucuronides and positively charged drugs and conjugates into the bile. It plays a similar role in renal elimination, while in other organs such as the placenta and the GIT it restricts the distribution of its substrates. Therefore, the primary role of MRP2 is to limit cellular exposure to its substrates. Dubin-Johnson syndrome patients possess an inherited mutation of the ABCC2 gene, giving rise to non-functional MRP2, and suffer from chronic hyperbilirubinemia. Although there are clinical DDIs ascribed to MRP2, and several drug substrates and inhibitors are known, MRP2 receives little attention in the current FDA guidance, and it is not mentioned in the EMA guidance. Nevertheless, investigations for NCEs should be considered on a case-by-case basis, particularly if hyperbilirubinemia is observed.

Localization

The predicted membrane topology of MRP2 transporter includes 12 transmembrane domains with at least two substrate-binding sites. MRP2 localizes to the apical membrane domain of polarized cells such as hepatocytes, renal proximal tubule cells, and intestinal epithelia, where it mediates unidirectional transport of substrates to the luminal side of the organ, therefore acting as an ATP-dependent efflux pump. MRP2 is also present in the gallbladder, bronchi, and placenta. Of the nine MRPs, only MRP2 localizes exclusively to the apical membrane of polarized cells.
In contrast with efflux transporters like MDR1 and BCRP, MRP2 is either absent or below detectable limits in the human blood–testis and blood–brain barriers. It is, however, present in brain capillaries of hippocampus specimens from patients with temporal lobe epilepsy, and in malignant tumor cells from renal clear-cell, hepatocellular, ovarian, colorectal, lung, breast, and gastric carcinomas (reviewed in [1]).

Function, physiology, and clinically significant polymorphisms

The localization of MRP2 supports a function in the terminal excretion and detoxification of endogenous and xenobiotic organic anions, particularly conjugates of glutathione (GSH), glucuronate or sulfate, as well as a contribution to resistance towards anticancer drugs targeting solid malignant tumors. MRP2 has a broad substrate specificity: it transports organic anions with the highest affinity for glucuronate, GSH conjugates of lipophilic substances (e.g. LTC4), sulfated bile salts [2], compounds without anionic conjugate residues (e.g. methotrexate and bromosulfophthalein), reduced and oxidized GSH, nucleotide analogues, and anticancer drugs. MRP2 transports conjugated endogenous and xenobiotic substances, including toxins and carcinogens, into the bile (from hepatocytes), urine (from renal proximal tubular cells), and the intestinal lumen (from enterocytes) [3]. The hepatic MRP2 pump contributes to the driving forces of bile flow and is the major transporter responsible for the biliary excretion of bilirubin glucuronides. Inhibitors of MRP2 include probenecid, cyclosporine, PSC833 and MK571.
MRP2 appears to have at least two substrate-binding sites, which demonstrate some inter-dependency. For example, in vitro glutathione (GSH) transport by MRP2 is stimulated by sulfinpyrazone at low concentrations, but at much higher concentrations, the latter occupies both transporter binding-sites, preventing the co-transport of glutathione, yet allowing sulfinpyrazone to be transported alone [4].
The majority of the >200 identified naturally occurring ABCC2 SNPs do not result in clinically relevant changes in function, but selected variants have been shown to alter the PK of clinical drugs. The hereditary disorder Dubin–Johnson syndrome is characterized by complete loss of functionally active MRP2, resulting chronic hyperbilirubinemia. In instances where sequence variants in the ABCC2 gene correlate with loss of MRP2 function, this is often compensated for by the upregulation of other membrane transporters with similar substrate specificities, notably MRP3 and MRP4, in the basolateral membrane of hepatocytes [5].
MRP2 expression is regulated at the transcriptional and post-transcriptional level by many endogenous and xenobiotic substances, and is altered in different disease states. Transcriptional levels may respond to changes in the intracellular concentrations of bile acids and other lipophilic compounds that are ligands for nuclear hormone receptors such as PXR, CAR, FXR and HNF4[6].

Clinical significance

MRP2 transports numerous clinically important compounds across multiple drug classes. Examples of clinical drug substrates include antibiotics such as ampicillin, azithromycin, and ceftriaxone; anticancer agents such as cisplatin, doxorubicin, irinotecan, and methotrexate; antihypertensives such as olmesartan and temocaprilate; and HIV drugs such as adefovir, lopinavir, and saquinavir [7]. MRP2 confers resistance to diverse chemoterapeutics such as cisplatin, methotrexate, mitoxantrone, and etoposide/teniposide. However, DDIs due to MRP2 modulation are difficult to describe for multiple reasons. To name a few, specific and potent clinical inhibitors and substrates are lacking; many MRP2 substrates are conjugated drug metabolites; and compensation by other MRPs (e.g. MRP3 and 4) may mask the effect of MRP2 on drug clearance. Thus, citations that discuss the involvement of MRP2 in DDIs typically refer to multiple transporters, including OATs, P-gp, BCRP, other MRPs, and OATPs.
Roughly half a dozen polymorphisms in the ABCC2 gene have been shown to be of clinical significance. The SNPs -24C/T, 1249G/A, 2366C/T, 3563T/A, 3972C/T, 4544G/A, and 4348G/A are associated with altered PK of irinotecan, pravastatin, methotrexate (MTX), mycophenolic acid, telmisartan, talinolol, tacrolimus, lopinavir, and doxorubicin. In particular, pediatric cancer patients carrying the MRP2 -24T allele show a gender-specific reduced methotrexate clearance, with -24T allele females having approximately 2-fold higher AUC versus non-variant patients, which results in more severe toxicities [8, 9]. Renal allograft recipients carrying the -24T or the 3972T allele showed a 17% increase in the AUC of mycophenolic acid [10]. The -24T allele also predisposes to diclofenac-induced hepatotoxicity [11], and increases the likelihood of resistance to antiepileptic drugs [12]. The 1249G>A polymorphism, on the other hand, appeared to decrease the risk of therapy resistance in Asian epileptic patients [13].
In addition to conjugated hyperbilirubinemia, Dubin-Johnson syndrome patients also have elevated urinary coproporphyrin ratios, which incidentally may provide quantitative information of in vivo MRP2 activity [14].

Regulatory requirements

Although there are several identified substrates and inhibitors of human MRP2, and a number of clinical citations on DDI and the impact of genetic polymorphisms, there is no specific recommendation for this transporter in the current FDA or EMA guidelines. Nonetheless, in vitro evaluation of the interactions of NCEs and particularly their conjugated metabolites should be considered on a case-by-case basis, especially where conjugated hyperbilirubinemia is observed.

Location Endogenous substrates In vitro substrates used experimentally Substrate drugs Inhibitors

hepatocytes (canalicular membrane), renal proximal tubule cells and enterocytes (luminal side), solid tumors

bilirubin and its conjugates, sulfated bile salts,
leukotriene C4
S-glutathionyl-estradiol,
cholecystokinin,
ethinylestradiol-3-O-glucuronide,
estrone 3-sulfate
bromosulfophthalein,
p-aminohippurate,
estradiol- 17b-glucuronide, CCK-8, sulfinpyrazone
glutathione and glucuronide conjugates, ampicillin, azithromycin, cefodezime, ceftriaxone, grepafloxacine, irinotecan, cisplatin, doxorubicin, epirubicin, vinblastine, vincristine, methotrexate, etoposide, mitoxantrone, valsartan, olmesartan, temocaprilate,
SN-38-gluc, adefovir, cidofovir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir

cyclosporine, delaviridine, efavirenz, emtricitabine, benzbromarone,
probenecid,
PSC-833

 

References

1.    Nies, A.T. and D. Keppler, The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch, 2007. 453(5): p. 643-59.
2.    Jemnitz, K., et al., ABCC2/Abcc2: a multispecific transporter with dominant excretory functions. Drug Metab Rev, 2010. 42(3): p. 402-36.
3.    Heredi-Szabo, K., et al., Potentiation of MRP2/Mrp2-mediated estradiol-17beta-glucuronide transport by drugs--a concise review. Chem Biodivers, 2009. 6(11): p. 1970-4.
4.    Evers, R., et al., Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer, 2000. 83(3): p. 375-83.
5.    Donner, M.G. and D. Keppler, Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver. Hepatology, 2001. 34(2): p. 351-9.
6.    Arana, M.R., et al., Physiological and pathophysiological factors affecting the expression and activity of the drug transporter MRP2 in intestine. Impact on its function as membrane barrier. Pharmacol Res, 2016. 109: p. 32-44.
7.    Chen, Z., et al., Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett, 2016. 370(1): p. 153-64.
8.    Rau, T., et al., High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther, 2006. 80(5): p. 468-76.
9.    Liu, Y., et al., Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia. PLoS One, 2014. 9(1): p. e82681.
10.    Naesens, M., et al., Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation, 2006. 82(8): p. 1074-84.
11.    Daly, A.K., et al., Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology, 2007. 132(1): p. 272-81.
12.    Xue, T. and Z.N. Lu, Association between the polymorphisms in the ATP-binding cassette genes ABCB1 and ABCC2 and the risk of drug-resistant epilepsy in a Chinese Han population. Genet Mol Res, 2016. 15(4).
13.    Wang, Y., et al., The recessive model of MRP2 G1249A polymorphism decrease the risk of drug-resistant in Asian Epilepsy: a systematic review and meta-analysis. Epilepsy Res, 2015. 112: p. 56-63.
14.    Benz-de Bretagne, I., et al., Urinary elimination of coproporphyrins is dependent on ABCC2 polymorphisms and represents a potential biomarker of MRP2 activity in humans. J Biomed Biotechnol, 2011. 2011: p. 498757.

Get our Transporter Book
  • 294 pages: All about transporters
  • 50 transporter monographs
  • Transporter-mediated drug interactions
  • Pros and cons of different assay types
  • The Extended Clearance Classification System
  • Regulatory requirements
  • Case studies

Get the Book